Meeting
2016 ASCO Annual Meeting
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).
Authors
Sylvia Adams
New York University Cancer Institute, New York, NY
Sylvia Adams , Jennifer Robinson Diamond , Erika Paige Hamilton , Paula Raffin Pohlmann , Sara M. Tolaney , Luciana Molinero , Xian He , Daniel Waterkamp , Roel Peter Funke , John D. Powderly II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01633970
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1009)
DOI
10.1200/JCO.2016.34.15_suppl.1009
Abstract #
1009
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
First Author: Leisha A. Emens
Poster
2018 ASCO Annual Meeting
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
First Author: Rebecca Dent
Poster
2017 ASCO Annual Meeting
DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab).
First Author: Steven H. Lin
Poster
2017 ASCO Annual Meeting
B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy.
First Author: Edward S. Kim